This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KAUFMANN, U. Articles by FROESCH, E. R. Search for Related Content PubMed PubMed Citation Articles by KAUFMANN, U. Articles by FROESCH, E. R.

Demonstration of a Specific Serum Carrier Protein of Nonsuppressible Insulin-like Activity in Vivo^*

Metabolic Unit, Department of Medicine, University of Zurich 8091 Zurich, Switzerland

The fate of nonsuppressible insulinlike activity (NSILA-S) was studied by injecting a tracer of ¹²⁵I-NSILA-S iv into rats. Ten minutes after injection of ¹²⁵I-NSILA-S alone, 20% of the label is found in serum, whereas after the injection of ¹²⁵I-insulin or ¹²⁵I-NSILA-S together with an excess of cold NSILA-S only 8% of the label are recovered. Sephadex G-200 chromatography at neutral pH of serum after injection of ¹²⁵I-NSILA-S reveals 2 peaks of radioactivity in the high molecular weight region at 67 and 47% bed volume. Five minutes after injection the peak at 67% starts to disappear, whereas the one at 47% persists with a half-life of 3 h. The latter peak was submitted to Sephadex G-200 chromatography at acidic pH which dissociates NSILA-S from its binding protein. The labeled material obtained by this procedure still exhibits the same binding characteristics to chick embryo fibroblasts as standard ¹²⁵I-NSILA-S. A third peak at 90% bed volume corresponding to low molecular NSILA-S is no longer detectable 20 min after injection. A fourth peak at 100% bed volume becomes apparent after 1 h. The half-life and chromatographic pattern of iv injected ¹²⁵I-NSILA-S are not changed by the simultaneous administration of insulin or growth hormone. These findings confirm the existence of a specific serum carrier protein for NSILA-S and may explain why endogenous NSILA-S does not exert insulinlike effects under physiological conditions in vivo.

Supported by grants of the Schweizerische Nationalfonds (3.7180.72).

^* Preliminary aspects of this study were reported in abstract form at the 11th Annual Meeting of the European Association for the Study of Diabetes in Munich, W. Germany, September 4-6, 1975.

Received April 14, 1976.

This article has been cited by other articles:

				P. M. Yamada and K.-W. Lee Perspectives in mammalian IGFBP-3 biology: local vs. systemic action Am J Physiol Cell Physiol, May 1, 2009; 296(5): C954 - C976. [Abstract] [Full Text] [PDF]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]

				A. Heding, R. Gill, Y. Ogawa, P. De Meyts, and R. M. Shymko Biosensor Measurement of the Binding of Insulin-like Growth Factors I and II and Their Analogues to the Insulin-like Growth Factor-binding Protein-3 J. Biol. Chem., June 14, 1996; 271(24): 13948 - 13952. [Abstract] [Full Text] [PDF]

				Z. Nevo and Z. Laron Growth Factors Arch Pediatr Adolesc Med, April 1, 1979; 133(4): 419 - 428. [Abstract] [PDF]